(PRWEB) August 29, 2005
Arbelos Capital Partners, a New York based research and consulting firm, today announced that it had published a new independent research report on Nanoscience Technologies Inc. Interested parties may obtain a copy of the report by contacting Arbelos at email@example.com, or by accessing the report directly from the interactive online community and informational website, DonPenny.com.
Arbelos Analyst Don Capo writes that, "Nanoscience Technologies is positioned to be a leader in this space [DNA Nanotechnology], and currently has an attractive valuation for an early stage investment.Â
About Nanoscience Technologies, Inc.
Nanoscience Technologies, Inc. combines business management, technology licensing and commercialization strategies to create a cohesive effort dedicated to delivering nanotechnology manufacturing solutions, nanodevices and nanomaterials to a wide range of industries worldwide. The Company's common equity is traded over-the-counter bulletin board. The Company holds exclusive license rights to technology developed by New York University's (NYU) 'Seeman Laboratory' headed by Dr. Nadrian C. Seeman, the inventor of DNA-based nanoscience.
About Arbelos Capital Partners
Arbelos Capital Partners, ÂResearch & Analysis for the 21st Century InvestorÂ is a New York based Research Consulting firm established to provide comprehensive research and analysis for institutional and individual investors. Arbelos is committed to providing:
- Independent Analysis
- Small-Cap & Micro-Cap Focus
- Proprietary Models and Ranking Systems
- Extreme Speculative Slant with Aggressive High Risk High Return Targets
- Unique Research Content based upon non-traditional factors
Arbelos is focused on isolating situations in the market that we believe will trade at a significant premium to the current day's stock price. Arbelos realizes that traditional measurements and models at times do not tell the entire story of a security. Experience has shown that as the market structure changes, investors also must change to adapt to the new factors that become more important in increasing the probability of earning a profit from an investment. Arbelos Models are based on risk return combinations and ranks of probabilities of price appreciation for each individual security. Arbelos analysts with a background in mathematics and economics have developed these proprietary models to assign significance to factors contributing to security valuations in the equity markets.
Arbelos has received no compensation for the writing of this report and is not affiliated with Nanoscience Technologies.
Disclaimer: Arbelos Capital Partners (Arbelos) is not registered as a broker dealer or an investment adviser and, as such, is not subject to regulation by the Securities and Exchange Commission, the national association of securities dealers or any similar regulatory authority. Arbelos does not deal, or make markets, in any securities. The information and opinions herein are for informational purposes only and are not intended to be recommendation or offer to sell, or a solicitation to buy, securities of any issuer. Brokers, dealer investment advisers and other financial intermediaries are encouraged to conduct their own independent investigation regarding the companies and securities herein. Arbelos specifically disclaims any liability, as disclosed at the conclusion of each separate profile. Arbelos may own securities in companies featured in its reports. Disclosure of consideration paid to Arbelos its publisher, officer, director, stockholders, employees, publishers' affiliates, agents, and/or family members, and/or any type of agreement Arbelos, its publisher, its officers, directors, stockholders, employees, publishers' affiliates, agents and/or family members may have with the companies reviewed in this publication, is disclosed. Arbelos has received no compensation for this report and this company represents part of Arbelos independent research and analysis program.
# # #